NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE American · Drug Manufacturers - Specialty & Generic · USD

Apimeds Pharmaceuticals US, Inc. (APUS) Stock Analysis

Apimeds Pharmaceuticals US, Inc. (APUS) is a Drug Manufacturers - Specialty & Generic stock listed on NYSE American and quoted in US Dollar.

Last Updated: October 21, 2026

APUS

$3.25

−$0.16 (−4.69%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare APUS with… →

APUS Key Statistics

As of Oct 21, 2026
Trading
Open
$3.51
Previous Close
$3.41
Day's Range
3.01–3.57
52-Week Range
1.51–59.70
Volume
128.00K
Valuation
Market Cap
$4.90M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−36.03
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$6.00M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.51M
1-Year Return
−82.89%
Dividend and dates
Avg Volume
3.76M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, APUS closed at $3.25, −82.89% over 1 year.

Apimeds Pharmaceuticals US, Inc. (APUS) has a market capitalization of $4.90M.

In fiscal 2025, APUS reported revenue of $0.00.

APUS Stock Return by Calendar Year

Apimeds Pharmaceuticals US, Inc. (APUS) return since May 2025: what $10,000 became

1 year
$10,000 $1,711
−82.89%
Since May 2025
$10,000 $1,477
−85.23%

If you had invested $10,000 in Apimeds Pharmaceuticals US, Inc. (APUS) at the close on May 9, 2025, the earliest close on record here, it would have been worth $1,477 at the close on October 21, 2026: −85.23% in total, −73.23% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−80.18%
2025 (partial year)−25.45%

As of October 21, 2026.

APUS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$6.00M—
2024$0.00−$1.39M—
2023$0.00−$777.69K—
2022$0.00−$668.67K—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$11.91M−$6.00M—
2024$0.00—−$1.28M−$1.39M—
2023$0.00—−$747.44K−$777.69K—
2022$0.00—−$639.53K−$668.67K—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Apimeds Pharmaceuticals US, Inc. (APUS) is capitalised at $4.90M on the latest close. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector.

The 52-week range on file runs from $1.51 to $59.70. The most recent close on file for APUS is $3.25, dated October 21, 2026. That is −$0.16 (−4.69%) against the previous close. The latest close sits 115.23% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $6.00M. Earnings per share on a trailing basis come to −36.03.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Daily returns over the trailing 1 year annualize to a volatility of 214.16%. Over the trailing twelve months the total return is −82.89%.

Growth & Income

The record shows no dividend for APUS.

So far in 2026 the total return is −80.18%.

Peer Comparison

Apimeds Pharmaceuticals US, Inc. (APUS) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Apimeds Pharmaceuticals US, Inc. APUS $4.90M —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Apimeds Pharmaceuticals US, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Apimeds Pharmaceuticals US, Inc.

Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.

Visit website →